Harte Hanks Inc. (HHS) Next Earnings Date & Expected ±8.6% Move

Per the Roarable RQD rating, HHS scores 41 out of 100 with a letter grade of D- and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The fundamental cash engine pillar scores 10 out of 20, reflecting ROIC of 2% and an FCF yield of -15.61%; for a prospective investor, this means the business is currently generating little return on capital and consuming cash relative to its market value. The whale 13F flow pillar scores 8 out of 20, indicating weak institutional accumulation and options positioning per the rating's inputs, so the upside case lacks visible large-holder support. The insider conviction pillar scores 3 out of 20, the lowest of the five, reflecting weak SEC Form 4 and Congressional PTR cluster flow; this offers little evidence of insider confidence. The macro regime fit pillar scores 9 out of 20, with a beta of 1.0 and sector sensitivity noted in the rating. The forensic balance sheet pillar scores 11 out of 20, citing an Altman Z of 14.61, a Piotroski F of 1 out of 9, and Debt/Equity of 0.5. The Altman Z figure is high, which on its face reads as solvency strength, but the very weak Piotroski F-Score signals poor fundamental quality across profitability, leverage, and efficiency tests, so a prospective investor should weigh these forensic readings against each other rather than treating the Z-Score alone as reassurance. Valuation tradeoffs are difficult to assess because P/E measures are not available in source data, while EV/EBITDA of 8.5 is present. The primary upside driver would be a sustained improvement in ROIC and free cash flow; the primary risk is continued cash burn against a $28.8M market capitalization.

Per the SEC financials, revenue declined across the three reported periods, and net income was negative in each. Per the market data, operating margin is 0.2%, net margin is -0.5%, and gross margin is 0%, with ROIC of 2%. Per the Roarable RQD rating, the Altman Z-Score is 14.61 and the Piotroski F-Score is 1 out of 9, with Debt/Equity of 0.5; the balance sheet shows modest cash balances of $5.6M in FY 2025 against negative free cash flow in the two most recent periods.

Per the recent news and catalysts section, five MarketBeat-, Yahoo! Finance Canada-, Stock Titan-, and TradingKey-type items were flagged YELLOW under MARKET WIRE, covering general market action and institutional positioning without specific fundamental detail. Two items flagged RED under RISK WATCH reference Q2 2025 earnings with a reported loss of $0.05 per share, one noting shares slipping 1.49% and one noting limited disclosure. Those RED items are the only risk-flagged catalysts in the source data. The Butterfly Supply-Chain Graph reports no supply chain links and no proprietary signals.

• What specific products and services generate HHS revenue, and how is revenue concentrated across customers?
• What are the trailing and forward earnings per share and price-to-earnings multiples, given that these are absent from the source data?
• What explains the gap between an Altman Z-Score of 14.61 and a Piotroski F-Score of 1 out of 9, and which balance sheet components drive each reading?
• What is the debt balance, since debt is reported as N/A across all periods despite a Debt/Equity ratio of 0.5?
• What is the cash runway given negative free cash flow and a FY 2025 cash balance of $5.6M?